Abstracts tagged "gout"

Abstract Number: 1864 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Rishi J. Desai¹, Jessica Franklin², Julia Spoendlin², Goodarz Danaei³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout patients have an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD); however, it is not…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Keith Petrie¹, Kate MacKrill¹, Christina Derksen² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Marburg, Marburg, Germany
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…
Abstract Number: 2052 • 2017 ACR/ARHP Annual Meeting
Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases
Zheng-Hao Huang¹, Chi-Ching Chang², En Chao³, Hui-Hsun Chiang⁴, Shu-Yi Lin⁵, Kun-Lin Wu⁶, Hsiang-Cheng Chen⁵, Shi-Jye Chu⁵, San-Yuan Kao⁵, Tsung-Yun Hou⁵, Feng-Cheng Liu⁵, Chen-Hung Chen⁷, Deh-Ming Chang⁸ and Chun-Chi Lu⁹, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital; Tri-service general hospital, National Defense Medical Center, Taipei, Taiwan, ²Taipei Medical University Hospital, Taipei, Taiwan, ³Tri-Service General Hospital Songshan Branch, Taipei, Taiwan, ⁴School of Nursing, National Defense Medical Center, Taipei, Taiwan, ⁵Tri-Service General Hospital, Taipei, Taiwan, ⁶Armed Forces Taoyuan General Hospital, Taipei, Taiwan, ⁷Taipei Tzu Chi hospital, Taipei, Taiwan, ⁸Taipei Veterans General Hospital, Taipei, Taiwan, ⁹University of Washington; Tri-Service General Hopsital, National Defense Medical Center, Seattle, WA
Background/Purpose: Gouty arthritis, caused by the deposition of monosodium urate (MSU) monohydrate crystals at joints, is comprised of multiple inflammatory processes in synovium, tendons, cartilages…
Abstract Number: 2084 • 2017 ACR/ARHP Annual Meeting
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Tristan Pascart¹, Laurène Norberciak², Hang-Korng Ea³, Sabine Lanz⁴, Charles Lambert⁵, Pascal Guggenbuhl⁶ and Frederic Liote⁷, ¹Rheumatology, Lille Catholic University, Lille, France, ²Lille Catholic University, Lille, France, ³INSERM UMR1132, Paris Diderot University, Paris, France, ⁴Laboratoire Mayoli Spindler, Chatou, France, ⁵Laboratoire Ipsen Pharma, Boulogne, France, ⁶Rennes University, Rennes, France, ⁷University Paris Diderot, Paris, France
Patients with Early Onset Gout develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions Background/Purpose: Early onset gout might encompass more severe cases along with genetic defects,…
Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…
Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Raquel Largo¹, Juan Pablo Medina², Sandra Perez-Baos², Victor Najera-Aleson², Aranzazu Mediero², Gabriel Herrero-Beaumont¹ and Esperanza Naredo³, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ³Rheumatology, Joint and Bone Research Unit, IIS-FJD, Hospital Universitario Fundación Jiménez Díaz., Madrid, Spain
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…
Abstract Number: 2087 • 2017 ACR/ARHP Annual Meeting
Allelic Variants of ABCG2 and Gout Risk
Blanka Stiburkova^1,2, Katerina Pavelcova^2,3, Jakub Zavada², Lenka Petru^2,3, Marketa Pavlikova^2,4, Hirotaka Matsuo⁵, Tony R. Merriman⁶ and Karel Pavelka⁷, ¹Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of probability and mathematical statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁵Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁷Institute of Rheumatology, Praha, Czech Republic
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. In…
Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Kenneth Saag¹, Michael A. Becker², Chris Storgard³, Maple Fung³, Jia Hu³ and Thomas Bardin⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago, Chicago, IL, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Hôpital Lariboisière, Paris, France
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
Abstract Number: 2022 • 2016 ACR/ARHP Annual Meeting
Developing a Gout Needs Assessment Incorporating Patient Perspective on Self-Management, Self-Efficacy and Disease Specific Knowledge, to Inform a Patient Education Initiative
Adam Rifaat¹, Adena Batterman², Roberta Horton² and Theodore R. Fields¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Social Work Programs, Hospital for Special Surgery, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis in adults, with great impact on quality of life. Despite excellent therapeutic options, outcomes remain suboptimal. Research supports…
Abstract Number: 2305 • 2016 ACR/ARHP Annual Meeting
Mapping the Topography of Gout Flares: Solutions for Flare Reporting in Gout Clinical Trials
Novell Teoh¹, Gregory Gamble², Anne Horne², William J. Taylor³, Kate Palmano⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Consultant Scientist, Waikato, New Zealand
Background/Purpose : Recurrent flares of inflammatory arthritis are the central clinical feature of gout. However, methods of gout flare reporting in research settings are inconsistent…
Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Ronald Berenson¹, Maura-Ann Matthews¹, Wayne Wallis², Raj Dua¹, Margaret Moore¹, Robert Terkeltaub³ and Christopher Clegg^1,4, ¹Aequus BioPharma, Inc., Seattle, WA, ²Dyad Life Sciences, LLC, Seattle, WA, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴TRIA Bioscience, Seattle, WA
Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
Abstract Number: 3071 • 2016 ACR/ARHP Annual Meeting
Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Marwa Qadri¹, Tannin Schmidt², Khaled Elsaid³ and Gregory Jay⁴, ¹Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ²Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, ⁴Emergency Medicine, Brown University, Providence, RI
Background/Purpose: Gout is an inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in synovial joints. MSU crystals interact with resident macrophages that…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].